HGH 191AA: Recombinant Human Growth Hormone Research Guide

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Written by Sophie Chen. Reviewed by Morgan Ellis, MSc Endocrinology · Last updated: 23 May 2026

Research-grade recombinant human growth hormone — frequently catalogued as HGH 191AA — is one of the most studied protein biologics on the planet, and one of the most misunderstood compounds inside the peptide-research community. This guide explains what the “191AA” suffix actually means, how the molecule is produced under HPLC-verified purity standards, what mechanism researchers exploit when investigating GH/IGF-1 axis biology, and how it differs from the GH-stimulator peptides (Sermorelin, CJC-1295, Ipamorelin, Tesamorelin) that often share shelf space with it.

What you’ll learn: the science of recombinant human growth hormone production; the dose ranges reported in published clinical and research literature; the difference between exogenous HGH 191AA and endogenous-release peptide stimulators; documented side-effect profiles; reconstitution and storage technique; and how to evaluate a Certificate of Analysis (COA) before committing to a research protocol.

Important framing: Throughout this guide, “research” is used in the technical sense — bench, animal, or human-subject investigations conducted under appropriate ethical and regulatory oversight. The molecule itself is offered as a research-grade laboratory reagent (CAS 12629-01-5; HPLC-verified purity; COA-keyed lots), not as a personal-use therapeutic. Always work within applicable local rules and institutional approvals.

What Is HGH 191AA?

HGH 191AA is recombinant human growth hormone — a 191-amino-acid polypeptide hormone, identical in primary sequence to the 22-kilodalton isoform secreted by somatotroph cells of the anterior pituitary, produced in laboratory expression systems (typically E. coli) and refolded into its native single-chain conformation with two intramolecular disulfide bridges.

The biologic was first cloned and expressed in 1979 by Goeddel and colleagues at Genentech, and commercial recombinant somatropin reached the market in 1985 — replacing pituitary-extracted growth hormone, which had been withdrawn following Creutzfeldt-Jakob disease cases linked to cadaveric contamination. Today, every legitimate commercial and research-grade preparation of HGH 191AA is recombinantly produced; pituitary-sourced hormone is no longer in use anywhere in the world.

Why the “191AA” naming convention matters

The pituitary actually secretes several isoforms of growth hormone. The dominant and most-studied form contains 191 amino acids with a molecular weight of approximately 22 kDa, and this is the form that recombinant production aims to recreate. A minor 20-kDa isoform (177 amino acids, missing residues 32–46) accounts for roughly 5–10% of total pituitary output; recombinant 192AA preparations carry an additional methionine residue at the N-terminus, the legacy of an older E. coli expression vector, and are now considered obsolete. The “191AA” suffix tells a researcher unambiguously that the product matches the dominant pituitary isoform exactly — no extra methionine, no truncations.

How HGH 191AA differs from peptide stimulators

This is the single most common point of confusion among newcomers to the field. HGH 191AA is the hormone itself, administered exogenously. Compounds like Sermorelin, Tesamorelin, CJC-1295, and Ipamorelin are secretagogues — they signal the body’s own pituitary to release endogenous growth hormone. The downstream physiology is similar, but the pharmacokinetic profile and side-effect curves diverge substantially. We unpack this in the alternatives section below; the foundational reference for the full landscape is the Best Growth Hormone Peptides hub.

How Does HGH 191AA Work? (Mechanism of Action)

Growth hormone biology is one of the cleaner stories in endocrinology, and worth working through in two layers: the molecular events at the receptor, and the systemic cascade that follows.

Layer 1: Receptor binding and JAK2/STAT5 signalling

HGH 191AA circulates partially bound to growth hormone binding protein (GHBP) and partially free. When the free fraction reaches a target cell, a single GH molecule binds two GH receptor (GHR) monomers, triggering receptor dimerisation. Pre-bound to the cytoplasmic tails of each GHR are JAK2 kinase molecules. Dimerisation brings the two JAK2 enzymes into proximity, allowing them to trans-phosphorylate each other and then phosphorylate tyrosine residues on the GHR cytoplasmic tail. STAT5 transcription factors dock at these phospho-tyrosine sites, are themselves phosphorylated, dimerise, translocate to the nucleus, and drive transcription of GH-responsive genes — most notably, hepatic IGF-1.

Parallel signalling pathways activate: PI3K/AKT (responsible for much of GH’s metabolic effect, including insulin antagonism), MAPK (proliferative signalling), and the SOCS family (negative-feedback proteins that terminate the GH signal within 30–60 minutes). The pulse-and-terminate kinetics of this signalling cascade are why pulsatile dosing patterns are clinically more physiological than constant-infusion strategies — sustained GH receptor occupancy drives SOCS upregulation and signal desensitisation.

Layer 2: The systemic GH/IGF-1 axis

Within 12–24 hours of administration, hepatic IGF-1 production rises, raising circulating IGF-1 concentration. IGF-1 mediates much (though not all) of GH’s anabolic action — stimulating amino acid uptake into skeletal muscle, driving chondrocyte proliferation at growth plates in immature subjects, and signalling through the IGF-1 receptor to promote satellite-cell activation and myofiber hypertrophy.

Direct (non-IGF-1-mediated) effects of GH include hormone-sensitive lipase activation in adipocytes (driving lipolysis), insulin antagonism in skeletal muscle and liver (the classic “diabetogenic” effect of GH excess), and stimulation of bone osteoblast activity. The therapeutic and research utility of HGH 191AA stems from this multi-layered cascade — body composition shifts toward lean mass, fasting glucose tends to rise, and IGF-1-mediated tissue repair accelerates.

Key Uses & Applications

HGH 191AA is approved as somatropin for several formal indications worldwide (paediatric growth hormone deficiency, adult GHD, Turner syndrome, idiopathic short stature, chronic kidney disease, AIDS wasting). In the research-peptide community, the molecule is most often investigated for the following endpoints — always under appropriate institutional/ethical oversight.

Body composition research (lean-mass gain, adipose reduction)

The Rudman 1990 New England Journal of Medicine study remains the most-cited single paper on GH and body composition — 12 men aged 61–81 receiving recombinant GH for 6 months showed an 8.8% rise in lean body mass and a 14.4% drop in adipose tissue versus baseline. Subsequent meta-analyses (Liu et al. Ann Intern Med 2007) confirmed the body-composition signal across many studies but emphasised that strength and functional outcomes did not improve in healthy older adults — a critical context point.

GH-deficiency replacement research

In adults with documented GHD (confirmed insulin-tolerance test or GHRH-arginine stimulation test), replacement HGH 191AA improves lipid profile, bone mineral density, exercise capacity, and quality-of-life metrics. Dosing in clinical practice is titrated to mid-normal IGF-1, typically starting at 0.2 mg daily and adjusting every 4–8 weeks based on serum IGF-1 response.

Tissue repair and post-injury research

GH and IGF-1 play documented roles in soft-tissue repair, including tendon, ligament, and skeletal muscle. Several studies have investigated short-course GH in the post-orthopaedic-surgery window. The mechanism is plausibly twofold: direct GH effect on satellite cell activation, and IGF-1-mediated collagen synthesis upregulation. Researchers studying this endpoint typically pair HGH 191AA with peptide adjuncts like BPC-157 or IGF-1 LR3.

Metabolic and sleep-architecture research

Exogenous GH alters insulin sensitivity (typically downward in the short term), shifts substrate utilisation toward free fatty acids, and modifies the architecture of deep sleep. Researchers interested in metabolic outcomes — fasting glucose, HOMA-IR, fatty-acid profiles — generally use lower physiologic-replacement doses; researchers interested in body-composition outcomes use higher doses but accept the metabolic trade-off.

Safety Profile, Side Effects & Dosing

The side-effect profile of HGH 191AA is one of the better-characterised in all of endocrinology because the molecule has been in clinical use for forty years. Effects scale predictably with dose, with cumulative exposure, and with baseline subject characteristics (older subjects and those with pre-existing insulin resistance show steeper curves).

Documented side effects

Dose ranges in published literature

• Adult GH deficiency replacement (clinical): 0.15–0.30 mg/day starting, titrated to mid-normal IGF-1; total daily dose usually settles at 0.2–0.6 mg (≈0.6–1.8 IU).
• Paediatric GH deficiency (clinical): 0.025–0.05 mg/kg/day, often weight-and-puberty-stage-stratified.
• Body-composition research (adult): 1–4 IU/day in published protocols; higher doses appear in older performance literature but carry steeper side-effect curves and metabolic disruption.
• AIDS wasting / specific high-dose indications: 4–6 mg/day documented; not generally relevant to peptide-research applications.

The IU↔mg conversion for recombinant somatropin is approximately 1 mg ≈ 3 IU (the exact ratio is 3.0 IU/mg per the WHO 98/574 reference standard). A 10-IU vial therefore contains roughly 3.33 mg of active polypeptide.

What Does the Research Say?

The research literature on recombinant human growth hormone is among the largest of any biologic. The summary below is a representative selection — not exhaustive — and focuses on landmark studies that have shaped current understanding.

Qualifying language matters: The body of work above supports a confident reading of mechanism, dose-response, and safety in formal clinical indications. Outside those — body-composition or anti-ageing research in subjects without documented GHD — the evidence is thinner and the risk/benefit equation is less favourable. Research-grade compound availability does not equal clinical justification.

HGH 191AA vs Alternatives — Comparison Table

This is the most useful single table in the article. Researchers and procurement managers most often misallocate budget by buying HGH 191AA when a peptide stimulator would have answered their experimental question more cleanly, or buy a stimulator when only the exogenous hormone produces the pharmacology they need.

How to decide

• Need direct exogenous hormone, full physiological cascade including supraphysiologic peaks: HGH 191AA.
• Want to preserve natural pulsatility and minimise pituitary suppression: Sermorelin, Tesamorelin, or Ipamorelin.
• Need both upstream stimulus and selective release without prolactin/cortisol rise: CJC-1295 (no-DAC) + Ipamorelin stack — see the dedicated CJC + Ipa stack guide.
• Want IGF-1 effects without GH-pulse and without pituitary feedback effects: IGF-1 LR3.
• Researching adipose tissue specifically, want lipolysis without IGF-1 rise: HGH Fragment 176-191.

How to Use HGH 191AA — Practical Research Guidance

Practical handling matters more for HGH 191AA than for many peptides because the molecule is comparatively delicate — refolded recombinant protein with two disulfide bonds, susceptible to aggregation and oxidation if mishandled.

Reconstitution

HGH 191AA ships as a lyophilised powder, typically 10 IU per vial. Reconstitution proceeds in three steps:

1. Bring vial to room temperature before opening (avoid temperature shock).
2. Inject bacteriostatic water down the inside wall of the vial — never directly onto the lyophilised cake — at a typical volume of 1 mL per 10 IU. The benzyl alcohol preservative in BAC water stabilises the reconstituted solution for 14–28 days refrigerated.
3. Swirl gently; do not shake. Shaking introduces foaming, which physically denatures protein. Let the cake dissolve over 30–60 seconds.

For the underlying reconstitution math and a printable reference, see our generalised reconstitution math guide and the dedicated BAC water guide.

Storage and stability

• Lyophilised vial (unopened): 2–8 °C refrigerated; manufacturer-claimed stability 18–36 months. Avoid freeze-thaw cycles.
• Reconstituted vial: 2–8 °C; use within 14–28 days. The benzyl alcohol in BAC water is the limiting reagent for long-term stability — Sterile Water for Injection without preservative limits useful reconstituted life to ~24 hours.
• Light protection: Store in original carton or opaque box. Tryptophan and tyrosine residues are mildly photolabile.
• Transport: Cold-chain only — see our peptide storage and cold-chain protocol for full handling rules.

Injection technique

Recombinant somatropin is conventionally administered subcutaneously into the abdominal wall, lateral thigh, or upper outer arm, using insulin syringes (29G or 31G, ½-inch needle). Rotate sites to avoid local lipoatrophy. Intramuscular administration is uncommon but documented in some research protocols; SC offers slower absorption and a longer time-to-peak, which more closely mimics endogenous secretion. For deeper coverage of the SC vs IM vs intranasal trade-offs across all peptides, see our peptide injection routes guide.

Cycling considerations

Sustained daily HGH 191AA administration drives SOCS-mediated receptor desensitisation, increases endogenous GH feedback suppression (pituitary GH secretion drops), and shifts the IGF-1 set-point. Many research protocols use 5-days-on / 2-days-off, 3-months-on / 1-month-off cycles, or weight-cycling between maintenance and higher-dose phases. The general principle: protect endogenous pulsatility wherever the research question allows.

Evaluating a Certificate of Analysis (COA)

Lot-to-lot variability is the single biggest threat to a clean research result. Every legitimate research-grade HGH 191AA vial should arrive with a batch-specific COA documenting:

• Purity by RP-HPLC: ≥98% main peak. Anything below 96% should be rejected.
• Identity by mass spectrometry: Observed molecular weight ≈22,124 Da (confirms 191-amino-acid backbone with native disulfide bonds).
• Aggregate content by size-exclusion HPLC: Monomer ≥97%, dimers and higher aggregates <3%.
• Bacterial endotoxin: <1 EU/mg (LAL test).
• Residual host-cell protein: <100 ng/mg.
• Bioassay (where included): Cell-based GH receptor activation, typically Nb2 lymphoma proliferation or HEK-GHR-STAT5 reporter, with ≥80% of reference standard activity.

A COA that lacks any of those rows is not a COA; it is a label.

Frequently Asked Questions

What is the difference between HGH 191AA and HGH 192AA?

The “192AA” designation refers to an older recombinant preparation that carried an extra N-terminal methionine residue as a byproduct of the E. coli expression vector. The 192AA form is functionally active but immunologically distinct from native pituitary GH, and modern manufacturing has moved entirely to 191AA, which matches the native 191-amino-acid pituitary sequence exactly. If a product is offered as “192AA”, that’s a signal of outdated manufacturing rather than a meaningful pharmacological difference.

How fast does HGH 191AA work?

Pharmacokinetically, a subcutaneous dose reaches peak plasma concentration in 3–6 hours, with a half-life of approximately 2–4 hours. Downstream IGF-1 rises within 12–24 hours and remains elevated for 24–36 hours. Phenotypic effects accrue over weeks: fluid retention and energy changes are usually noticed within 1–2 weeks; body-composition shifts (lean mass up, fat mass down) become measurable over 6–12 weeks of consistent administration; bone mineral density changes require 12+ months.

Does HGH 191AA cause cancer?

This is the most-asked safety question and deserves a precise answer. Adult GHD replacement therapy has been studied for over thirty years of post-marketing follow-up; large-cohort surveillance studies (KIMS, Pfizer International Metabolic Database, ANSWER) have not demonstrated increased malignancy risk when GH is dose-titrated to mid-normal IGF-1. Supraphysiologic chronic dosing (the acromegaly model) is associated with modestly increased risk of colon polyps and possibly other tumours. The practical inference: dose-titrated replacement appears safe over decades; chronic supraphysiologic dosing is biologically distinct and carries genuine cancer-surveillance considerations. Active malignancy is a contraindication.

What’s the right time of day to administer HGH 191AA?

Endogenous GH peaks in the first half of deep sleep (typically 90–120 minutes after sleep onset). Research protocols seeking to mimic physiology often administer in the evening, 2–4 hours before bedtime, allowing the exogenous peak to overlap with the endogenous nocturnal pulse. Split-dose protocols (morning + evening) increase total IGF-1 exposure but may attenuate the body’s own nighttime peak via feedback. For non-physiologic research designs (body composition, athletic-research models), morning dosing has been used to avoid sleep disturbance.

Can HGH 191AA be taken orally?

No. Recombinant HGH is a 191-amino-acid polypeptide; oral administration would result in proteolytic degradation in the gastrointestinal tract long before any meaningful systemic absorption. Subcutaneous or intramuscular injection are the only viable routes for the intact molecule. (Oral GH “spray” or “sublingual” products on the market do not contain bioavailable GH and should not be confused with the injectable biologic.)

How do I tell if my HGH 191AA is real?

Three signals matter, in order: (1) a batch-specific Certificate of Analysis documenting ≥98% HPLC purity, mass-spectrometry molecular-weight confirmation, and endotoxin testing; (2) physical appearance — proper lyophilised cake (white, dry, uniform) that dissolves cleanly in BAC water within 60 seconds without foaming or visible particulates; (3) biological response — measured IGF-1 rise on serum testing 12–24 hours after a 2-IU dose, which legitimate research-grade material reliably produces. Inability to produce IGF-1 elevation despite multiple doses indicates either denatured or counterfeit material.

What’s the difference between HGH 191AA and a GH secretagogue?

HGH 191AA is growth hormone — the same molecule the pituitary secretes — administered exogenously. A secretagogue (Sermorelin, CJC-1295, Tesamorelin, Ipamorelin) is a separate peptide that signals the pituitary to release its own stored GH. Pharmacologically, the consequence is that secretagogues cannot exceed the pituitary’s stored release capacity and preserve the body’s natural pulsatility and feedback regulation; exogenous HGH 191AA bypasses both the limit and the feedback, allowing supraphysiologic exposures but at the cost of pituitary suppression on prolonged administration.

Do I need bacteriostatic water to reconstitute HGH 191AA?

For any reconstituted vial intended to be used over multiple days, yes — bacteriostatic water with 0.9% benzyl alcohol is the standard diluent and extends in-use stability to 14–28 days refrigerated. Plain Sterile Water for Injection is acceptable for single-use same-day reconstitution but does not provide antimicrobial protection for multi-day vials. Saline (0.9% NaCl) is also occasionally used but offers neither preservative protection nor an obvious advantage over BAC water.

The Bottom Line

HGH 191AA is the foundational biologic in the growth-hormone landscape — the actual recombinant 191-amino-acid hormone, identical to native pituitary somatropin, produced under HPLC-verified purity standards and used across clinical replacement therapy and a wide range of research protocols. It is mechanistically distinct from — and pharmacologically more potent than — the secretagogue peptides (Sermorelin, CJC-1295, Ipamorelin, Tesamorelin) that occupy adjacent shelves and addresses different research questions. The side-effect profile is well-characterised, dose-responsive, and most strongly tied to cumulative supraphysiologic exposure rather than short-window administration.

For researchers selecting between HGH 191AA and a peptide stimulator, the most useful framing is: do I need exogenous hormone exposure with supraphysiologic peaks, or do I need amplified endogenous pulsatile release? The former answers the body-composition and lipolysis research questions more cleanly; the latter answers physiology-preservation research questions more cleanly. Both have legitimate roles. Both require COA-verified lots, cold-chain handling, and structured protocols.

Explore our research-grade HGH 191AA with batch COA documentation, or compare against the full growth-hormone-peptide landscape in our Best Growth Hormone Peptides hub. The complete peptide catalogue covers GHRH analogues (Sermorelin, Tesamorelin, CJC-1295), GHRPs (Ipamorelin), and downstream effectors (IGF-1 LR3, HGH Fragment 176-191).

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.